المفاهيم الأساسية
Advancements in HER2-amplified colorectal cancer treatment have led to promising outcomes with targeted therapies like tucatinib and trastuzumab.
الإحصائيات
"We see HER2-amplified or HER2-positive disease in about 3% of patients."
"Response rate was 46% in the MOUNTAINEER study."
"Confirmed objective response rate was 38% in combined cohorts A plus B."
"Trastuzumab deruxtecan showed a response rate of 45% in the DESTINY-CRC01 study."
"Response rate for trastuzumab deruxtecan was 38% at the lower dose of 5.4 mg/kg."
اقتباسات
"It was an opportunity to make an impact on a field that was still highly dependent on traditional chemotherapy."
"If you use a standardized, Clinical Laboratory Improvement Amendments–(CLIA)-certified assay, and it says it's HER2 amplified or overexpressed, odds are pretty good that the patient will benefit from anti-HER2 therapies."
"The lesson is, number one, test for HER2 right out of the gate."